pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
KRAS · news · pharmadog
← back to KRAS
News · KRAS
87
stories
1d
STAT+: One of the most consequential years for cancer treatment, ever
stat
8d
Chutes & Ladders—Former Legend CEO lands at K2
fiercebiotech
8d
PDS halts work on phase 3 cancer therapy to focus on colorectal contender
fiercebiotech
10d
RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win
endpoints
14d
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
18d
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
fiercebiotech
23d
Incyte cuts early-stage cancer drug to focus on next-gen programs
biospace
Jul 17, 26
BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
fiercebiotech
Jul 14, 26
Erasca's $550M offering; Summit sells an antibiotic
endpoints
Jul 6, 26
STAT+: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms
stat
Jul 6, 26
STAT+: Four major biotech updates to catch up on
stat
Jul 6, 26
STAT+: GOP lawmakers push Trump’s FDA to make sure clinical trials are diverse
stat
Jul 6, 26
STAT+: I spoke to Anthropic’s CEO about how AI may affect biotech. Here’s what I learned
stat
Jul 2, 26
STAT+: What does DeGette’s loss mean for pharma?
stat
Jul 2, 26
Revolution Medicines shares promising data around KRAS drug combination
endpoints
Jul 2, 26
Roche KRAS drug succeeds in head-to-head lung cancer study
biopharma dive
Jul 2, 26
STAT+: Roche drug sets new standard for KRAS-driven lung cancer
stat
Jul 2, 26
Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 study
endpoints
Jun 26, 26
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
biopharma dive
Jun 15, 26
Elicio’s KRAS cancer vaccine fails in Phase 2, shares plummet
endpoints
Jun 11, 26
Summit pulls $500M share sale a day after announcing it
biopharma dive
Jun 11, 26
STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&A
stat
Jun 10, 26
STAT+: Hope for Kendall Square’s lab market
stat
Jun 9, 26
STAT+: Trump’s health care affordability czar takes aim at hospitals
stat
Jun 9, 26
Stealthy startup Treeline plans a reverse merger
biopharma dive
Jun 9, 26
Gilead and Merck’s latest trial success and flop
stat
Jun 8, 26
STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
stat
Jun 8, 26
Tango data add to growing momentum for pancreatic cancer drugs
biopharma dive
Jun 8, 26
J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B
biopharma dive
Jun 8, 26
J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field
endpoints
← prev
page 1 of 3
next →
